Korea Institute of Radiological & Medical Sciences

Futurechem Co., Ltd

Kyo Chul Lee

Sang Moo Lim

Yong Jin Lee

Min Hwan Kim

Dae Yoon Chi

Byoung Se Lee

Se Young Oh

So Young Chu

Joo Hyun Kang

Ji Ae Park

Hyeon Jin Jeong

Mi Hyun Kim

Kyeong Min Kim

Eun Ju Kim

Sang Keun Woo

Woon Jung Jung

Ran Ji Yoo

Jung Young Kim

Wook Kim

Jong Guk Kim

Sang June Jeon

The present invention relates to a radiopharmaceutical distribution image generation system and method using deep learning and, more specifically, to a radiopharmaceutical distribution image generation system and method using deep learning, wherein dynamic medical images collected from multiple patients and a time-radiation dose distribution curve for each organ can be learnt through a deep learning network and a spatial distribution image of a radiopharmaceutical can be generated from a static medical image acquired from a specific patient. According to the present invention, even when a medical image is acquired only for a specific time after a radiopharmaceutical is injected into a patient, a spatial distribution image of the radiopharmaceutical can be acquired across the entire time by using the deep learning network, and quantitative analysis of the radiopharmaceutical can be performed by calculating a time-radiation dose distribution curve on the basis thereof.

Radiopharmaceutical distribution image generation system and method using deep learning

The present invention relates to a pharmaceutical composition for diagnosing and treating prostate cancer, capable of targeting PSMA, and a compound provided by one aspect of the present invention has a glutamine-urea-lysine compound to which a radioactive metal-coupled chelator is structurally coupled and to which an aryl group that can additionally bind to PSMA protein is coupled. Coupling between the glutamine-urea-lysine compound and the chelator includes a polar spacer so as to serve the role of reducing in vivo nonspecific coupling and exhibit an effect of being rapidly removed from vital organs, but not from prostate cancer. These characteristics lower the radiation exposure, which is caused by a therapeutic radioisotope-coupled compound, to normal tissue and organs, and thus reduce side effects. In addition, a compound that contains a phenyl group having a coupling force with albumin has an increased residence time in the blood, thereby becoming more accumulated in prostate cancer.

PSMA-targeted radiopharmaceutical for diagnosing and treating prostate cancer

The disclosure provide an apparatus for producing a nuclide by using a liquid target which can perform the nuclear reaction process and can discharge the radioactive gas such as Radon within the vial. As described above, an apparatus for producing a nuclide by using a liquid target according to the present disclosure can minimize quantitative loss of a reactant by performing the nuclear reaction process using a target of a liquefied state and reusing a liquefied target on which the nuclear reaction process has not been performed, and can improve safety by enabling the radioactive gas generated to be disposed.

Apparatus of producing nuclide using fluid target

A method of producing actinium by using liquefied radium includes producing Ac-225 using Ra-226 of a liquefied state, moving the produced Ac-225 in a liquefied state after Ac-225 is produced, and separating Ac-225 and reusing Ra-226. As a result, a nuclear reaction process of Ac-225 may be performed and loss of Ra-226 may be minimized. Further, such a method may improve safety by including a radon collection unit which is capable of discharging and isolating radon produced from Ra-226, thereby preventing radiation exposure due to radon.

Method of producing actinium by irradiating liquefied radium with a particle beam

The present invention relates to an 18F-labelled compound, and a use thereof. The compound selectively binds to a prostate-specific membrane antigen (PSMA), and enables the acquisition of clear prostate cancer images in a short time when used in positron emission tomography (PET).

18F-labelled compound for prostate cancer diagnosis, and use thereof

Provided is a polyhedral-shaped radiation counter which measures a radiation level of a radioactive material, in which sensor modules configured to measure the radiation level are disposed at vertexes of a polyhedral shape, respectively, and the sensor modules are connected to each other by rod-shaped frame members disposed in edge positions of the polyhedral shape and face parts of the polyhedral shape form an open space.

Polyhedral-shaped radiation counter

Growing community of inventors

Seoul, South Korea

Kyo Chul Lee